HIV/AIDS Clinical Care: Archives

SUMMARY AND COMMENT

A Glimmer of Hope for HIV VaccinesFree

• October 22, 2009
• Frances H. Priddy, MD, MPH, and Carlos del Rio, MD

A large trial has shown that a vaccine can protect against HIV acquisition. The task now is to figure out how to build on this initial success.

• Reviewing:
• Rerks-Ngarm S et al., N Engl J Med 2009 Oct 20 Dolin R., N Engl J Med 2009 Oct 20

SUMMARY AND COMMENT

A Better Way to Allocate ADAP Resources

• October 19, 2009
• Abigail Zuger, MD

When state funds cannot pay for everyone's antiretroviral therapy, treating high-risk patients first minimizes morbidity and mortality.

• Reviewing:
• Linas BP et al., J Acquir Immune Defic Syndr 2009 Aug 15; 51:513

SUMMARY AND COMMENT

Resistance Development with Tenofovir/FTC vs. AZT/3TCFree

• October 19, 2009
• Jonathan Z. Li, MD, and Paul E. Sax, MD

In a comparative clinical trial, patients receiving tenofovir/FTC were less likely to develop resistance mutations during virologic failure than were those receiving AZT/3TC.

• Reviewing:
• Margot NA et al., J Acquir Immune Defic Syndr 2009 Oct 1; 52:209

SUMMARY AND COMMENT

HIV-Associated Pulmonary Arterial Hypertension Defies ARTFree

• October 9, 2009
• Abigail Zuger, MD

A large case series suggests that the prognosis of PAH is not dramatically altered by effective combination antiretroviral therapy.

• Reviewing:
• Degano B et al., AIDS 2009 Sep 16

SUMMARY AND COMMENT

Switching from Enfuvirtide to Raltegravir — Safe and Effective?

• October 9, 2009
• Charles B. Hicks, MD

New trial results support making such a switch while continuing both the NRTIs and the PIs in the original regimen.

• Reviewing:
• De Castro N et al., Clin Infect Dis 2009 Oct 15; 49:1259

FEATURE

Clinical Management of Opioid Dependence in HIVFree

• October 5, 2009
• Mark Eisenberg, MD

Here we present a case vignette highlighting a common clinical problem. Various options for management are then presented, followed by the author's clinical recommendations.

SUMMARY AND COMMENT

Inflammatory Biomarkers and Risk for Opportunistic Disease

• October 5, 2009
• Keith Henry, MD

Higher levels of IL-6 and hsCRP at baseline and over time were associated with the development of opportunistic disease in the SMART study.

• Reviewing:
• Rodger AJ et al., J Infect Dis 2009 Sep 15; 200:973

SUMMARY AND COMMENT

How High Should the CD4 Cells Go?

• September 28, 2009
• Abigail Zuger, MD

A huge analysis concludes only that higher is better.

• Reviewing:
• The Antiretroviral Therapy Cohort Collaboration., J Acquir Immune Defic Syndr 2009 Aug 7

NEWS IN CONTEXT

HIV Vaccine Study Shows PromiseFree

• September 28, 2009
• Frances H. Priddy, MD, MPH

A new vaccine regimen, tested among more than 16,000 young adults, was found to offer modest protection against HIV acquisition.

• Reviewing:
• McNeil DG Jr., New York Times 2009 Sep 24 U.S. Military HIV Research Program 2009 Sep 24 U.S. Military HIV Research Program., 2009 Sep 24 U.S. Military HIV Research Program., 2009 Sep 4

SUMMARY AND COMMENT

Testing for and Prevalence of HCV Infection in HIV-Infected Patients

• September 28, 2009
• Sonia Nagy Chimienti, MD

During a 12-year observational study among HIV-infected patients, the prevalence of HCV coinfection decreased from 37% to 20%.

• Reviewing:
• Spradling PR et al., J Acquir Immune Defic Syndr 2009 Sep 4